Stargardt Disease – Epidemiology Insights and Forecast Report – 2020 To 2040

Stargardt Disease Epidemiology Insights

Thelansis’s “Stargardt Disease Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Stargardt Disease Overview

Stargardt disease is a rare, inherited macular dystrophy that leads to progressive central vision loss, typically beginning in childhood or adolescence, and is most commonly caused by mutations in the ABCA4 gene. This genetic defect disrupts the normal transport of vitamin A derivatives in photoreceptor cells, resulting in the accumulation of toxic lipofuscin within the retinal pigment epithelium, which damages the macula—the part of the retina responsible for sharp, detailed vision. Patients often report blurred vision, difficulty reading, and increased sensitivity to light, while peripheral vision usually remains preserved. The condition follows an autosomal recessive inheritance pattern and is diagnosed through fundus imaging, optical coherence tomography (OCT), electroretinography, and genetic testing.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Stargardt Disease – Epidemiology Insights and Forecast Report – 2020 To 2040